United States: USPTO Releases Patent Eligibility Update

On May 4, 2016, the USPTO released a "May 2016 Subject Matter Eligibility Update" ("Update") providing guidance to patent examiners on formulating a subject matter eligibility rejection and evaluating an applicant's response to that rejection. The USPTO concurrently released new life science examples to assist examiners and applicants evaluate whether claimed discoveries satisfy 35 U.S.C. § 101 in view of recent decisions by the U.S. Supreme Court and the Federal Circuit. Of importance to those seeking to patent diagnostic methods key to personalized medicine, the recent update provides guidance on whether diagnostic and treating claim present patent eligible subject matter.

Diagnosing and Treating Julitis

All new examples build on and further illustrate the USPTO's two-part analysis described in the USPTO's Interim Eligibility Guidance, wherein if a claim is decided to be directed to an abstract idea, a law of nature, or a natural phenomenon, then the claim must be evaluated to determine if the claim elements taken individually and in combination, amount to something significantly more than the exception itself.

New example 29 "diagnosing and treating julitis" is noted to illustrate the application of the significantly more analysis to diagnostic and treatment claims using a hypothetic autoimmune disease – julitis. The hypothetical patent applicant discovered the presence of a protein known as "JUL-1" in a patient and discovers that it is a maker for the disease. The applicant discloses in her application that one can detect the marker "JUL-1" by routine and conventional methods such as by physical biopsy of patient tissue, or by immunoassays in which a patient sample is contacted with an antibody to the JUL-1 protein, and then by detecting any complex formed between the protein and antibody using a laboratory technique such as fluoroscopy. Antibodies that can be used for the detection of the JUL-1 protein-antibody complex include naturally occurring antibodies (such as a polyclonal antibody) and a non-naturally occurring antibody (for example a porcine antibody or a monoclonal antibody).

The example notes that prior to applicant's invention, porcine antibodies were not routinely or conventionally used to detect human proteins such as JUL-1. The example also states that prior to applicant's invention, julitis was conventionally treated with anti-tumor necrosis factor (TNF) antibodies, but not all patients were responsive to the TNF therapy. Applicant discovered that certain patients, even those non-responsive to TNF therapy, did respond to treatment with vitamin D. Vitamin D had not previously been used to treat julitis.

Representative Claims

Seven exemplary claims are provided by the USPTO, and reproduced below:

1. A method of detecting JUL-1 in a patient, said method comprising:

a. obtaining a plasma sample from a human patient; and

b. detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with an anti-JUL-1 antibody and detecting binding between JUL-1 and the antibody.

2. A method of diagnosing julitis in a patient, said method comprising:

a. obtaining a plasma sample from a human patient;

b. detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with an anti-JUL-1 antibody and detecting binding between JUL-1 and the antibody; and

c. diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected.

3. A method of diagnosing julitis in a patient, said method comprising:

a. obtaining a plasma sample from a human patient;

b. detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with a porcine anti-JUL-1 antibody and detecting binding between JUL-1 and the porcine antibody; and

c. diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected.

4. A method of diagnosing julitis in a patient, said method comprising:

a. obtaining a plasma sample from a human patient;

b. detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with antibody mAb-D33 and detecting binding between JUL-1 and antibody mAb-D33; and

c. diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected.

5. A method of diagnosing and treating julitis in a patient, said method comprising:

a. obtaining a plasma sample from a human patient;

b.detecting whether JUL-1 is present in the plasma sample;

c. diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected; and

d. administering an effective amount of topical vitamin D to the diagnosed patient.

6. A method of diagnosing and treating julitis in a patient, said method comprising:

a. obtaining a plasma sample from a human patient;

b. detecting whether JUL-1 is present in the plasma sample;

c. diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected; and

d. administering an effective amount of anti-tumor necrosis factor (TNF) antibodies to the diagnosed patient.

7. A method of treating a patient with julitis, the method comprising administering an effective amount of anti-TNF antibodies to a patient suffering from julitis.

Of the exemplary claims, claims 1 and 3-7 were deemed to satisfy 35 U.S.C. § 101. Claim 2 is not eligible, because the claim is directed to a judicial exception without reciting something more than the exception itself.

Claim 1 is eligible and claim 2 is not, even though claim 2 (as compared to claim 1) recites the additional element of "diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected." Claim 1 is a straight detection claim whereas claim 2, with the addition of element "c" correlates the detection of the JUL-1 protein with a positive diagnosis of julitis. As explained by the Update, it is the absence of the diagnosis step that saves the claim because it fails to recite any judicial exception. The Update explains that although nature-based product limitations are recited in the claim (e.g., the plasma sample and JUL-1), an analysis of the claim as a whole indicates that the claim is focused on a process of detecting the JUL-1 protein, and not a product per se. For that reason, there is no reason to evaluate the claim under the second of the two step analysis, i.e., whether the claim recites something more than the judicial exception itself.

Claim 2 is not eligible because it recites a judicial exception – element c. drawn to the correlation of JUL-1 and julitis). Therefore the claim as whole must be evaluated to determine if it recites something more than the exception itself. The claim elements of gathering the sample and using conventional techniques to determine if JUL-1 is present in the sample, are conventional and routine and do not add something beyond the judicial exception. The example contrasts this claim to the claims considered under Diehr, which were individually conventional, added "something more" when combined to improve a technical field.

Similar to claim 2, claim 3 is directed to a judicial exception because it recites an element requiring a diagnosis of julitis. However, because the claim requires the use of a porcine antibody which was not known in the art for the detection of human JUL-1 protein, the use of the porcine antibody is an unconventional step that is more than a mere instruction to apply the correlation and critical thinking step (the judicial exception) using well-understood, routine or conventional techniques in the field. For the same reason, claim 4, requiring the use of the antibody mAb-D33 (which was not routinely used to detect human JUL-1 protein), is patent eligible.

Claims 5 and 6 are directed to diagnosing julitis by detecting if JUL-1 protein is present in a patient sample and then administering a particular therapy to the patient diagnosed with julitis. Claim 5 is eligible because the step of administering vitamin D to treat julitis was not conventional at the time the invention was made, and therefore the administration step adds "something more" to the claim. For claim 6, the administration of the particular therapy adds meaningful limits on the use of the exception steps of the claim and therefore is patent eligible.

Claim 7 is patent eligible because, while reciting a nature-based product limitation (the anti-TNF antibodies), an analysis of the claim as a whole indicates that the claim is focused on the practical application of that product and therefore is patent eligible.

Patents and Personalized Medicine 

The Update and in particular, the example directed to diagnostic and therapeutic methods, is welcomed by those seeking patent protection for diagnostic methods that are routinely used in personalized medicine. The Update is a clear indication that diagnostic methods, if not broadly drawn only to a correlation or relationship between a detected marker in a patient sample and a disease state, are patentable subject eligible.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions